Compare AdaptHealth Corp (AHCO) vs Jones Lang LaSalle Inc (JLL) Price & Performance

AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.

The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.

JLL trades at $332.57, up 1.56% today, with a bullish technical outlook and strong earnings momentum after beating Q1 2026 EPS estimates. Revenue grew to $26.12B in 2025, with net income reaching $792.10M and improving margins. Positive analyst sentiment includes a $405.50 consensus price target, and recent news highlights strategic growth initiatives and inclusion on Zacks Strong Buy lists as of June 2026.

The stock presents a favorable risk-reward profile with a 22% upside to the consensus target, supported by robust cash flow generation and debt reduction. Key risks include economic sensitivity and competitive pressures, but institutional backing and consistent earnings beats underpin a constructive outlook for patient investors.